sRANK Ligand (Human) OmniKine ELISA Kit

Catalog No.

OK-0161

Size

12 x 8-Well Microstrips

Price

530.00€

Buy

Product details

Description

The OmniKine Human sRANK-Ligand ELISA can be used to reconize both recombinant and naturally produced (by human) Human sRANK-Ligand proteins. The following antigens were tested at 50 ng/ml and showed less than 1% cross reactivity. • Human: sRANKR, TNFalpha, TWEAK. Those tested at 50 ng/ml and did not showed significant interference or cross reactivity. • Human: sFASL, IL-20, TNFbeta, sTRAIL, 4-1BBL, sCD40L, Eotaxin-3, • Rat: sRANKL, TNFalpha • Murine: sRANKL, TNFalpha

Target Name

Human sRANK Ligand

Assay Type

Sandwich ELISA

Detection Method

Colorimetric 450 nm

Synonyms

Tumor necrosis factor receptor superfamily member 11A, Receptor activator of NF-KB, CD265, Osteoclast differentiation factor receptor.

NCBI Gene Symbol

TNFRSF11A

Storage

4°C

Stability

6 Months

Dynamic Range

63-4000 pg/ml

Recommended use

Research use only

Contact us

Contact us by Live Chat or by Email at ask@gentaur.com

Technical Service

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Properties

E05 478 566 350 170 or Enzyme-Linked Immunosorbent Assays,E05 478 566 350 170 or Enzyme-Linked Immunosorbent Assays,Human proteins, cDNA and human recombinants are used in human reactive ELISA kits and to produce anti-human mono and polyclonal antibodies. Modern humans (Homo sapiens, primarily ssp. Homo sapiens sapiens). Depending on the epitopes used human ELISA kits can be cross reactive to many other species. Mainly analyzed are human serum, plasma, urine, saliva, human cell culture supernatants and biological samples.

Test

ELISA Enzyme-linked immunosorbent assays Code 90320007 SNOMED

Additional description

FAS ligand and other ligands are binding to the receptor for signaling pathways for example in apoptosis or JNK signaling. Receptor agonists are often tested for drug development.